Predict your next investment

Corporation
esperopharma.com

See what CB Insights has to offer

About Espero Pharmaceuticals

Espero Pharmaceuticals is a commercial-stage cardiovascular pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular category.

Espero Pharmaceuticals Headquarter Location

14286-19 Beach Blvd #270

Jacksonville Beach, Florida, 32250,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Espero Pharmaceuticals News

Espero BioPharma Assets Offered For Sale

Jun 25, 2020

Espero BioPharma Assets Offered For Sale 6/25/20 Espero BioPharma, Inc. is focused on the development of drugs for the treatment of cardiorenal diseases. The company, a private Delaware corporation, is the result of a 2017 business combination between Espero Pharmaceuticals, Inc. and Armetheon, Inc. The company's portfolio of products includes: (i) tecarfarin, a Phase III-ready oral anti-coagulant with FDA orphan drug designation for patients with End Stage Renal Disease (ESRD) and atrial fibrillation (AFib) and (ii) DURLAZA (aspirin Extended Release Capsules, 162.5mg), an FDA-approved antiplatelet therapy. The U.S. has a $13 billion-dollar oral anticoagulant market. ESRD patients with AFib is a distinct population within this market and Espero's tecarfarin is a potential solution for this high-risk group with no currently FDA-approved therapies. Rock Creek Advisors, LLC ( www.rockcreekfa.com ) is serving as Espero's Financial Advisor and is selling the assets of Espero BioPharma, Inc., including all intellectual properties, patent portfolio, formulations, URLs and trademarks associated with its names and brands as well as clinical trial results and related data to drug development. General Bid Deadline is July 28, 2020 at 5 p.m. (EDT)

Espero Pharmaceuticals Acquisitions

2 Acquisitions

Espero Pharmaceuticals acquired 2 companies. Their latest acquisition was Armetheon on March 30, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/30/2017

Series B

$99M

$31.3M

Merger

1

2/7/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/30/2017

2/7/2017

Investment Stage

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$31.3M

Note

Merger

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.